Pneumonia is a major risk factor of death after acute stroke. Preventive antibacterial therapy with Moxifloxacin not only prevents the development of post-stroke infections, it also reduces mortality, and improves neurological outcome significantly.
Randomized, double-blind, placebo-controlled trial in 80 with severe, non-lacunar, ischemic stroke (NIHSS>11) in the middle cerebral artery (MCA) territory. Injections received were either intravenous moxifloxacin (400 mg daily) or placebo for 5 days starting within 36 hours after stroke onset. Preventive administration of moxifloxacin is superior in reducing infections after severe non-lacunar ischemic stroke compared to placebo. In addition, the results emphasize the pivotal role of immunodepression in developing post-stroke infections.
No comments:
Post a Comment